The Effect of Bone Morphogenetic Protein-2 on Osteosarcoma Metastasis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Mar 7

PMID 28264040

Citations 9

Authors

Jonathan Gill

Patrick Connolly

Michael Roth

So Hak Chung

Wendong Zhang

Sajida Piperdi

Bang Hoang

Rui Yang

Hillary Guzik

Jonathan Morris

Richard Gorlick

David S Geller

Affiliations

Soon will be listed here.

Abstract

Purpose: Bone Morphogenetic Protein-2 (BMP-2) may offer the potential to enhance allograft-host osseous union in limb-salvage surgery following osteosarcoma resection. However, there is concern regarding the effect of locally applied BMP-2 on tumor recurrence and metastasis. The purpose of this project was to evaluate the effect of exogenous BMP-2 on osteosarcoma migration and invasion across a panel of tumor cell lines in vitro and to characterize the effect of BMP-2 on pulmonary osteosarcoma metastasis within a xenograft model.

Experimental Design: The effect of BMP-2 on in vitro tumor growth and development was assessed across multiple standard and patient-derived xenograft osteosarcoma cell lines. Tumor migration capacity, invasion, and cell proliferation were characterized. In addition, the effect on metastasis was measured using a xenograft model following tail-vein injection. The effect of exogenous BMP-2 on the development of metastases was measured following both single and multiple BMP-2 administrations.

Results: There was no significant difference in migration capacity, invasion, or cell proliferation between the BMP-2 treated and the untreated osteosarcoma cell lines. There was no significant difference in pulmonary metastases between either the single-dose or multi-dose BMP-2 treated animals and the untreated control animals.

Conclusions: In the model systems tested, the addition of BMP-2 does not increase osteosarcoma proliferation, migration, invasion, or metastasis to the lungs.

Citing Articles

Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions.

Frankenbach-Desor T, Niesner I, Ahmed P, Durr H, Klein A, Knosel T Cancer Metastasis Rev. 2024; 44(1):8.

PMID: 39592467 PMC: 11599440. DOI: 10.1007/s10555-024-10218-2.

Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research.

Giusti V, Miserocchi G, Sbanchi G, Pannella M, Hattinger C, Cesari M Biomedicines. 2024; 12(8).

PMID: 39200384 PMC: 11352184. DOI: 10.3390/biomedicines12081921.

Chitosan-Boric Acid Scaffolds for Doxorubicin Delivery in the Osteosarcoma Treatment.

Dornjak L, Kovacic M, Ostojic K, Angaits A, Szpunar J, Urlic I Polymers (Basel). 2022; 14(21).

PMID: 36365746 PMC: 9656110. DOI: 10.3390/polym14214753.

Full-length transcriptome and analysis of bmp-related genes in .

Wu X, Gong Q, Chen Y, Liu Y, Song M, Li F Heliyon. 2022; 8(10):e10783.

PMID: 36276739 PMC: 9582708. DOI: 10.1016/j.heliyon.2022.e10783.

Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years.

Ehata S, Miyazono K Front Cell Dev Biol. 2022; 10:883523.

PMID: 35693928 PMC: 9174896. DOI: 10.3389/fcell.2022.883523.

References

Jia S, Worth L, Turan M, Kleinerman E . Eradication of osteosarcoma lung metastasis using intranasal gemcitabine. Anticancer Drugs. 2002; 13(2):155-61. DOI: 10.1097/00001813-200202000-00007. View

Geng S, Sun B, Lu R, Wang J . Coleusin factor, a novel anticancer diterpenoid, inhibits osteosarcoma growth by inducing bone morphogenetic protein-2-dependent differentiation. Mol Cancer Ther. 2014; 13(6):1431-41. DOI: 10.1158/1535-7163.MCT-13-0934. View

Rici R, Alcantara D, Fratini P, Wenceslau C, Ambrosio C, Miglino M . Mesenchymal stem cells with rhBMP-2 inhibits the growth of canine osteosarcoma cells. BMC Vet Res. 2012; 8:17. PMC: 3307475. DOI: 10.1186/1746-6148-8-17. View

Guo W, Gorlick R, Ladanyi M, Meyers P, Huvos A, Bertino J . Expression of bone morphogenetic proteins and receptors in sarcomas. Clin Orthop Relat Res. 2000; (365):175-83. DOI: 10.1097/00003086-199908000-00023. View

Bielack S, Kempf-Bielack B, Delling G, Exner G, Flege S, Helmke K . Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20(3):776-90. DOI: 10.1200/JCO.2002.20.3.776. View

Friedrich J, Moran S, Bishop A, Wood C, Shin A . Free vascularized fibular graft salvage of complications of long-bone allograft after tumor reconstruction. J Bone Joint Surg Am. 2008; 90(1):93-100. DOI: 10.2106/JBJS.G.00551. View

Gobbi G, Sangiorgi L, Lenzi L, Casadei R, Canaider S, Strippoli P . Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol. 2001; 20(1):143-7. View

Ayerza M, Farfalli G, Aponte-Tinao L, Muscolo D . Does increased rate of limb-sparing surgery affect survival in osteosarcoma?. Clin Orthop Relat Res. 2010; 468(11):2854-9. PMC: 2947695. DOI: 10.1007/s11999-010-1423-4. View

Wang L, Park P, Zhang H, La Marca F, Claeson A, Valdivia J . BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line. Cancer Biol Ther. 2010; 11(5):457-63. PMC: 3230314. DOI: 10.4161/cbt.11.5.14372. View

10.

Mirabello L, Troisi R, Savage S . International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009; 125(1):229-34. PMC: 3048853. DOI: 10.1002/ijc.24320. View

11.

Jia S, Worth L, Kleinerman E . A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis. 2000; 17(6):501-6. DOI: 10.1023/a:1006623001465. View

12.

Simon M, Aschliman M, Thomas N, Mankin H . Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am. 1986; 68(9):1331-7. View

13.

Hornicek F, Gebhardt M, Tomford W, Sorger J, Zavatta M, Menzner J . Factors affecting nonunion of the allograft-host junction. Clin Orthop Relat Res. 2001; (382):87-98. DOI: 10.1097/00003086-200101000-00014. View

14.

Houghton P, Morton C, Tucker C, Payne D, Favours E, Cole C . The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2006; 49(7):928-40. DOI: 10.1002/pbc.21078. View

15.

Haydon R, Luu H, He T . Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res. 2006; 454:237-46. DOI: 10.1097/BLO.0b013e31802b683c. View

16.

Yang R, Hoang B, Kubo T, Kawano H, Chou A, Sowers R . Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer. 2007; 121(5):943-54. DOI: 10.1002/ijc.22749. View

17.

Garrison K, Donell S, Ryder J, Shemilt I, Mugford M, Harvey I . Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess. 2007; 11(30):1-150, iii-iv. DOI: 10.3310/hta11300. View

18.

Luo X, Chen J, Song W, Tang N, Luo J, Deng Z . Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest. 2008; 88(12):1264-77. PMC: 9901484. DOI: 10.1038/labinvest.2008.98. View

19.

Geller D, Singh M, Zhang W, Gill J, Roth M, Kim M . Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2. Clin Cancer Res. 2014; 21(13):3003-12. DOI: 10.1158/1078-0432.CCR-14-0986. View

20.

Jaffe N, Carrasco H, Raymond K, Ayala A, Eftekhari F . Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?. Cancer. 2002; 95(10):2202-10. DOI: 10.1002/cncr.10944. View